Form 6-K NewcelX Ltd. For: Jun 15

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the Month of June 2026

 

Commission File Number: 001-39957

 

NEWCELX LTD.

(Translation of registrant’s name into English)

 

Hohstrasse 1, 8302 Kloten

Switzerland

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

☒ Form 20-F ☐ Form 40-F

 

 

 

CONTENTS

 

On June 15, 2026, NewcelX Ltd., a corporation incorporated under the laws of Switzerland, issued a press release titled: “NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology Platform.” A copy of this press release is furnished herewith as Exhibit 99.1.

 

 

EXHIBIT INDEX

 

Exhibit Number		Description of Document
99.1		Press release titled: “NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology Platform”

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	NewcelX Ltd.
Date: June 15, 2026	By:	/s/ Ronen Twito
		Name:	Ronen Twito
		Title:	Chief Executive Officer

 

 

ATTACHMENTS / EXHIBITS

PRESS RELEASE TITLED: "NEWCELX PUBLISHES PEER-REVIEWED STUDY DEMONSTRATING BROAD THERAPEUTIC POTENTIAL OF ITS STEM CELL TECHNOLOGY PLATFORM"

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology Platform
• Utopai Studios and Huace Partner on Fully AI-Generated “Journey to the West” Animated Series and Theatrical Franchise
• Lakewood-Amedex Biotherapeutics Secures Composition of Matter Patent Protecting New Bisphosphocin® Compounds Being Developed for High-Need Antimicrobial Infections